昭衍新药8月13日晚间公告，公司原副董事长左从林因自身资金需求，计划自2025年8月19日至2025年8 月29日期间，通过集中竞价或大宗交易方式减持公司股份不超过352.45万股，即不超过公司总股本的 0.4703%。减持价格将根据市场价格确定。本次减持计划实施具有不确定性。 ...

截至本公告披露日，北京昭衍新药研究中心股份有限公司（以下简称"公司"） 原副董事长左从林（已离任）持有公司股份 14,098,317 股，占公司总股本 1.8811%。 上述股份来源于首发前限售股份、股权激励股份及公司资本公积金转增股份等。 减持计划的主要内容 左从林因自身资金需求，计划根据市场价格情况，自本公告披露之日起 3 个 交易日后即 2025 年 8 月 19 日至 2025 年 8 月 29 日内通过集中竞价或大宗交易的 方式减持其所持有公司股份不超过 3,524,500 股，减持比例不超过公司总股本的 0.4703%，减持计划实施期间，公司若发生送红股、转增股本、增发新股或配股 等股本除权事项的，减持数量将进行相应调整。 股东名称 左从林 股东身份 控股股东、实控人及一致行动人 □是 √否 直接持股 5%以上股东 □是 √否 董事、监事和高级管理人员 □是 √否 其他：原副董事长 持股数量 14,098,317股 持股比例 1.8811% 当前持股股份来源 IPO 前取得：3,649,000股 其他方式取得：10,449,317股 证券代码：603127 证券简称：昭衍新药 公告编号：2025- ...

人民财讯8月13日电，昭衍新药（603127）8月13日晚间公告，公司原副董事长左从林(已离任)计划通过 集中竞价或大宗交易方式，减持公司股份不超过352.45万股，减持比例不超过公司总股本的0.47%。 ...

智通财经APP讯，昭衍新药(06127)公布，公司原副董事长左从林(已离任)因自身资金需求，计划根据市 场价格情况，自本公告披露之日起 3 个交易日后即 2025 年 8 月 19 日至 2025 年 8 月 29 日内通过集中竞 价或大宗交易的方式减持其所持有公司股份不超过352.45万股，减持比例不超过公司总股本的 0.4703%，减持计划实施期间，公司若发生送红股、转增股本、增发新股或配股等股本除权事项的，减 持数量将进行相应调整。 （原标题：昭衍新药(06127)股东左从林拟减持公司股份不超过352.45万股） ...

昭衍新药公告，原副董事长左从林因自身资金需求，计划根据市场价格情况，自本公告披露之日起3个 交易日后即2025年8月19日至2025年8月29日内，通过集中竞价或大宗交易的方式减持其所持有公司股份 不超过3524500股，减持比例不超过公司总股本的0.4703%。 (本文来自第一财经) ...

昭衍新药（603127）(06127)公布，公司原副董事长左从林(已离任)因自身资金需求，计划根据市场价格 情况，自本公告披露之日起3个交易日后即2025年8月19日至2025年8月29日内通过集中竞价或大宗交易 的方式减持其所持有公司股份不超过352.45万股，减持比例不超过公司总股本的0.4703%，减持计划实 施期间，公司若发生送红股、转增股本、增发新股或配股等股本除权事项的，减持数量将进行相应调 整。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年8月13日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 ...

Market Performance - On August 13, the medical services sector rose by 4.02%, led by Innovative Medical [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - The table lists various stocks in the medical services sector, with notable declines including *ST Bio down 4.95% and ST Zhongzhu down 2.66% [1] - Other stocks such as Lanwei Medical and Baicheng Pharmaceutical also experienced minor declines of 1.76% and 1.59% respectively [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.962 billion yuan from institutional investors, while retail investors experienced a net outflow of 1.888 billion yuan [3] - Notable stocks with significant net inflows from institutional investors include Yaoming Kande with 1.13 billion yuan and Kanglong Huacheng with 248 million yuan [3] - Conversely, retail investors showed significant outflows from stocks like Yaoming Kande and Kanglong Huacheng, indicating a shift in investor sentiment [3]

Market Overview - A-shares experienced a significant rally, with the Shanghai Composite Index achieving an 8-day winning streak and reaching a new high since December 2021, closing at 3683.46 points, up 0.48% [1] - The total trading volume in the A-share market exceeded 2 trillion yuan for the first time since February 27, with a total of 21,756 billion yuan traded [1] - The Hong Kong stock market also saw substantial gains, with the Hang Seng Index rising over 2% and the Hang Seng Tech Index increasing over 3% [1] AI Industry - AI-related stocks surged, with notable gains including Guangku Technology and Robotech both hitting the 20% limit up, and Industrial Fulian also reaching the limit up [2][4] - Industrial Fulian reported a revenue of 360.76 billion yuan for the first half of 2025, a year-on-year increase of 35.58%, and a net profit of 12.11 billion yuan, up 38.61% [4][5] - The demand for AI servers is expected to grow significantly, driven by increased capital expenditures from major North American cloud service providers [4][5] Innovative Pharmaceuticals - The innovative drug sector saw strong performance, with Shouyao Holdings hitting the 20% limit up, and other companies like Microchip Biotech and WuXi AppTec also posting significant gains [6][8] - The National Medical Insurance Administration has established a "new drug pricing mechanism," which is expected to provide innovative drug manufacturers with greater pricing flexibility and efficiency [8] Humanoid Robotics - The humanoid robotics sector showed renewed activity, with companies like Shenglan Co. and Jieke Co. seeing substantial increases in stock prices [9][11] - The World Robot Conference held in Beijing highlighted advancements in embodied intelligent robots, with local governments offering subsidies for robot purchases [9][11] - The industry is expected to benefit from various supportive policies and events, including the upcoming World Humanoid Robot Games and other robotics-related conferences [11]

Group 1: Market Performance - The three major indices showed strong performance, with the Shanghai Composite Index rising by 0.48%, surpassing last year's October high, while the Shenzhen Component Index increased by 1.76% and the ChiNext Index surged by 3.62% [1] - Over 2,600 stocks in the two markets experienced gains, with a total trading volume of approximately 2.15 trillion yuan [1] Group 2: Sector Highlights - The computing power, liquid cooling servers, and CPO concept stocks performed exceptionally well, with New Yisheng (300502.SZ) rising over 15%, and other notable gains from Zhongji Xuchuang (300308.SZ) at 11.66% and Cambridge Technology (603083.SH) at 9.93% [1] - PEEK materials saw collective strength, with companies like Huami New Materials (836247.BJ) and Xinhang New Materials (301076.SZ) experiencing significant increases [2] - The non-ferrous metals sector also performed well, with Electric Alloy (300697.SZ) rising over 9% and other companies like Luoyang Molybdenum (603993.SH) and Zhongfu Industrial (600595.SH) showing strong gains [2] Group 3: Economic Insights - Citic Securities noted that poor economic and employment data in the U.S. strengthened market expectations for a Federal Reserve rate cut in September, contributing to a broad rise in the non-ferrous metals sector [3] - The domestic push for "anti-involution" to optimize production factors is expected to enhance profitability across various sectors, benefiting metal prices [3] - The valuation of industrial metals is currently low, indicating potential for upward correction, with a bullish market for non-ferrous metals starting to emerge [3] Group 4: Policy and Market Sentiment - Dongguan Securities highlighted active market sentiment, suggesting an overweight position in the financial sector due to supportive policies aimed at enhancing the attractiveness of domestic capital markets [4] - The number of new A-share accounts opened in July reached 1.96 million, a significant year-on-year increase of 71%, indicating rising market participation and potential business opportunities for the securities industry [4] - Some sectors, including banks, coal, and logistics, experienced declines, with notable drops in stocks like Lu'an Huaneng (601699.SH) and Jiangsu Bank (600919.SH) [4]